WCG Insights Home » Articles » Clinical Researcher: Getting the Right Signatures on Informed Consent Documents
Request a Genetics in Clinical Trials training sessionWhat You'll Learn
Most Recent Flipbooks
The Right Way to Use Genetic Information in Clinical Trials
Q&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
Q&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
Trend: Genetic Testing and Data Privacy Ownership
Adverse Event Reporting: When TMI is Risky
Optimizing Global Safety Reporting in Clinical Trials
CNS Drugs Take Longer to Develop, Win Approval
CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
Master Protocols Can Kickstart Clinical Trials
WCG, Inspire Team Up to Boost Trial Access
Are Scientists Closing in on Treatments for Schizophrenia's Most Elusive Symptoms?
Researchers, buoyed by a spike in promising clinical trials and tools, believe they may be close to unraveling new ways to treat some of the most insidious yet elusive effects of schizophrenia
IRBs can make the most of central IRB partnerships
The IRB at Inova Health System of Falls Church, VA, began working with a central IRB 15 years ago. Since then, the IRB developed a well-organized process for its partnerships with independent IRBs.
Navigation Through Fair Market Value Ambiguity
Conquer Study Start-Up Delays With a Data-Driven Approach
A new approach to solving start-up delays is built on this foundation of advanced data analytics and accelerates study start-up timelines by 33 percent.
FDA Posts First List of Surrogate Endpoints
Genetics in Precision Medicine: A Data Management Issue
Finding Good Sites in Today’s Competitive Site Landscape
Improving Clinical Site Payment Practices
IRBs and IBCs: Critical Partners in Gene Research
Improving Subject Selection and Endpoint Management in Alzheimer's Trials
DMC Regulations May Change, but Principles Won't